ADAM17 and its proteolytic targets in disease pathogenesis
The FEBS Journal · 2026-08 · 293 (16) · 4789-4804
DOI: 10.1111/febs.70516 ↗At a glance
Übersichtsarbeit in The FEBS Journal, published online on 2026-03-23. Written by Abdulbasit Amin and 1 co-authors. Institution: Gulbenkian Institute for Molecular Medicine (GIMM), Lisbon, Portugal. Major MEDLINE topics: ADAM17 Protein, Neoplasms, Inflammation, ADAM Proteins. 74 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
ADAM17, from the disintegrin and metalloproteinase (ADAM) family, also called tumor necrosis factor converting enzyme (TACE), is a pleiotropic protease with more than 90 substrates, including growth factors, cytokines, receptors, and adhesion molecules. The biology of ADAM17 has been extensively studied, mainly as a regulator of epidermal growth factor receptor (EGFR) and tumor necrosis factor (TNF) signaling pathways, which are crucial for growth and inflammation, respectively. Consequently, this protease has been considered a major target to treat human cancers and inflammatory disorders. Moreover, it is involved in the pathobiology of numerous other disease types. This review summarizes the current understanding of ADAM17 and the involvement of its targets in inflammation, cancer, and cardiovascular and metabolic diseases.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Gulbenkian Institute for Molecular Medicine (GIMM), Lisbon, Portugal.
- Department of Physiology, Faculty of Basic Medical Sciences, University of Ilorin, Nigeria.
- Veterinary Medicine Research (I-MVET), Faculty of Veterinary Medicine, Lusófona University - Lisbon University Center, Portugal.
- Veterinary and Animal Research Center (CECAV), Faculty of Veterinary Medicine, Lusófona University - Lisbon University Center, Portugal.
- Superior School of Health, Protection and Animal Welfare, Polytechnic Institute of Lusophony (IPLUSO), Lisbon, Portugal.
ORCID profiles: Marina Badenes
Cite
APA
Amin, A., & Badenes, M. (2026). ADAM17 and its proteolytic targets in disease pathogenesis. The FEBS Journal, 293(16), 4789-4804. https://doi.org/10.1111/febs.70516
Vancouver
Amin A, Badenes M. ADAM17 and its proteolytic targets in disease pathogenesis. The FEBS Journal. 2026;293(16):4789-4804. doi:10.1111/febs.70516
BibTeX
@article{Amin2026,
author = {Amin, Abdulbasit and Badenes, Marina},
title = {ADAM17 and its proteolytic targets in disease pathogenesis},
journal = {The FEBS Journal},
year = {2026},
volume = {293},
number = {16},
pages = {4789--4804},
doi = {10.1111/febs.70516}
}
EUVIMED